CN102038745A - Hypolipidemic traditional Chinese medicine - Google Patents
Hypolipidemic traditional Chinese medicine Download PDFInfo
- Publication number
- CN102038745A CN102038745A CN2009102186235A CN200910218623A CN102038745A CN 102038745 A CN102038745 A CN 102038745A CN 2009102186235 A CN2009102186235 A CN 2009102186235A CN 200910218623 A CN200910218623 A CN 200910218623A CN 102038745 A CN102038745 A CN 102038745A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- merging
- hypolipidemic
- blood fat
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 230000000055 hyoplipidemic effect Effects 0.000 title abstract 5
- 241000222336 Ganoderma Species 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims abstract description 5
- 238000010992 reflux Methods 0.000 claims abstract description 5
- 239000008280 blood Substances 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 22
- 244000113306 Monascus purpureus Species 0.000 claims description 17
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 17
- 229940057059 monascus purpureus Drugs 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract description 2
- 241000228347 Monascus <ascomycete fungus> Species 0.000 abstract 2
- 238000000034 method Methods 0.000 description 8
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000008802 xuezhikang Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940021171 curative drug Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229930195732 phytohormone Natural products 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a hypolipidemic traditional Chinese medicine comprising the following materials by thousand grain weight: 150-220 grams of monascus, 2500-3300 grams of radix salviae miltiorrhizae and 4800-5600 grams of lucid ganoderma. The hypolipidemic traditional Chinese medicine is prepared sequentially according to the following steps of: a. lixiviating the radix salviae miltiorrhizae twice through heating and reflux by utilizing ethanol, merging and concentrating an extracting solution to form thin paste; b. crushing the lucid ganoderma, adding water to decoct twice, and merging and filtering a decoction solution; c. merging dregs of a decoction, which are obtained from the step (a) and the step (b), adding an appropriate quantity of water for decoction, filtering the decoction solution, merging with filter liquor obtained from the step (b), and then concentrating to the thin paste; d. merging thin paste materials obtained from the step (a) and the step (c), and adding fine monascus powder and an appropriate quantity of auxiliary materials to prepare grains or capsules or tablets. The hypolipidemic traditional Chinese medicine is proved to have obvious effects on the aspect of reducing hypercholesterolemia and hypertriglyceridemia through clinical comparison and is superior to hypolipidemic products in the prior art.
Description
Technical field
The invention belongs to a kind of Chinese medicine, what be specifically related to is a kind of Chinese medicine of blood fat reducing.
Background technology
Along with improving constantly of people's living standard, the sickness rate of hyperlipemia is obvious ascendant trend, and hyperlipemia is again the key factor of bringing out coronary atherosclerotic heart disease (coronary heart disease), arteriosclerosis, fatty liver, diabetes, obesity etc.Therefore the blood lipid-lowering medicine of seeking high effect nontoxic has important practical sense.At present a lot of to the drug research of hyperlipemia, curative drug mainly is divided into Western medicine and Chinese medicine two big classes.The curative effect of Western medicine is more remarkable, and particularly statins has demonstrated increasing market potential, but these medicines are in blood fat reducing, can cause blood sugar increasing, feels sick, untoward reaction such as abdominal distention, diarrhoea and liver function injury.And Chinese medicine has special advantages in this respect, and its medicine source is abundant, and untoward reaction is few, and curative effect is more definite, and multiple effect for reducing blood fat approach is arranged again, has broad application prospects.Recent study finds that Monas cuspurpureus Went has good lipid-lowering effect, is at present that the blood lipid-lowering medicine of raw material production has " Xuezhikang " and " zhibituo " two kinds on the market with the Monas cuspurpureus Went, and the test report that tool is relevant shows that the clinical efficacy of Xuezhikang is better than zhibituo.Yet these two kinds of medicines are because raw material all has only the Monas cuspurpureus Went Herba indigoferae Pseudotinctoriae, and its performance is single.
The traditional Chinese medical science belongs to hyperlipemia insufficiency of the spleen phlegm-damp, qi depression to blood stasis, caused by liver and kidney deficiency etc. clinically, according to putting down in writing in the Compendium of Material Medica, Monas cuspurpureus Went has the effect of strengthening the spleen to promote digestion, be a kind of " insufficiency of the spleen phlegm-damp " at its syndrome, and " caused by liver and kidney deficiency " and " qi depression to blood stasis " two disease types are failed to relate to, significant limitation is arranged on clinical treatment.
Summary of the invention
The objective of the invention is to overcome deficiency of the prior art, propose a kind of blood fat reducing Chinese medicine, be used for the treatment of hyperlipemia.
The technical scheme that realizes above-mentioned purpose is: a kind of blood fat reducing Chinese medicine, by the weight of thousand amounts, get Monas cuspurpureus Went 150～220g, and Radix Salviae Miltiorrhizae 2500～3300g, Ganoderma 4800～5600g, and undertaken by following step successively:
A. Radix Salviae Miltiorrhizae alcohol heating reflux lixiviate twice, each 1.5 hours, the extracting solution merging was concentrated into rare paste;
B. Ganoderma powder is broken into coarse powder, decocts with water 2 times, each 3 hours, decocting liquid merged filtration;
C. with above-mentioned (a) and (b) the medicinal residues merging in step, add suitable quantity of water and decocted 2 hours, decocting liquid filters, and filtering decocting liquid and above-mentioned (b) step filtrate merge, and concentrated this filtrate is to rare paste;
D. with above-mentioned (a) and (c) rare paste merging in step, add Monas cuspurpureus Went fine powder and appropriate amount of auxiliary materials and make granule, drying.
In the such scheme, to be respectively be 90% and 50% to twice used concentration of ethanol in described (a) step.
In the such scheme, twice amount of water is respectively 10 times of amounts and 8 times of amounts of Ganoderma in described (b) step.
In the such scheme, the amount of water in described (c) step is for merging 5 times of amounts of medicinal residues.
According to the method described above, can adopt existing medicament forming technique to be processed into capsule or tablet etc.
Hyperlipemia belongs to three disease types such as insufficiency of the spleen phlegm-damp, qi depression to blood stasis, caused by liver and kidney deficiency on tcm clinical practice, so when treatment is many with strengthening the spleen to promote digestion, blood circulation promoting and blood stasis dispelling, the liver and kidney tonifying three therapeutic methods of traditional Chinese medicine.Be that principal agent is monarch drug with the Monas cuspurpureus Went in the blood fat reducing Chinese medicine of the present invention, contain multiple digestive enzyme composition in the Monas cuspurpureus Went, effect with strengthening the spleen to promote digestion, and contain abundant bioactive enzyme and several physiological active substances, as: can reduce the Monascus anka Nakazawa et sato metabolite such as material Monacolin-K, ergosterol, γ-An Jidingsuan, natural phytohormone of human serum cholesterol, have high nutrition, health care, medical value; Radix Salviae Miltiorrhizae has blood circulation promoting and blood stasis dispelling as ministerial drug, the effect of calming heart and tranquilizing mind; Ganoderma is an adjuvant, and the effect of liver and kidney tonifying, tranquilizing by nourishing the heart, brain-strengthening arresting convulsion is arranged.
Blood fat reducing Chinese medicine of the present invention compares with existing " Xuezhikang " clinical, and each treats case 22 examples, and compares with Western medicine " clofibrate " treatment, and therapeutic outcome is as follows:
Annotate: the dose of Chinese medicine of the present invention is 2/time, and 3 times/day, 14 days is a course of treatment.
By last table as can be seen, except that descending to cholesterol, the Xuezhikang group do not see the difference that all the other are respectively organized, and all there were significant differences before curative effect was controlled.Illustrate that of the present invention group of medicine effect aspect reduction hypercholesterolemia and hypertriglyceridemia is obvious, Xuezhikang effect aspect triglyceride reducing is also good.From top argumentation and clinical trial as can be seen, the therapeutic effect of blood fat reducing Chinese medicine of the present invention is better than at present existing procucts on the market.
The specific embodiment
The present invention will be further described below in conjunction with embodiment.
Embodiment 1.
Get Monas cuspurpureus Went 200g, Radix Salviae Miltiorrhizae 3000g, Ganoderma 5000g, and undertaken by following step successively:
A. Radix Salviae Miltiorrhizae powder is broken into coarse powder, extracted 1.5 hours with 90% alcohol heating reflux earlier, filter extracting solution, reuse 50% alcohol heating reflux 1.5 hours filters extracting solution, and extracted twice liquid merges, and reclaims ethanol and concentrated extracting solution to rare paste, and medicinal residues are continued to employ;
B. Ganoderma powder is broken into coarse powder, adds 10 times of water gagings earlier and decocted 3 hours, filter decocting liquid, add 8 times of decoctings again and boiled 3 hours, filter decocting liquid, medicinal residues are continued to employ;
C. Radix Salviae Miltiorrhizae decoction dregs and Ganoderma medicinal residues are merged, add 5 times of water gagings and decocted 2 hours, filter decocting liquid, filtering decocting liquid and above-mentioned (b) step filtrate merge, and concentrate this filtrate to rare paste;
D. with above-mentioned (a) and (c) rare paste merging in step, add Monas cuspurpureus Went fine powder and appropriate amount of auxiliary materials and make 1,000 granules, dry back packing.
Can in undried granule of above-mentioned (d) step, add some adjuvants again, the film coating tablet that adopts existing medicament forming technique to be processed into 1122.
Embodiment 2.
Get Monas cuspurpureus Went 150g, Radix Salviae Miltiorrhizae 2500g, Ganoderma 4800g makes granule according to embodiment 1 described method, the dry 480g that gets.If in granule, add adjuvant, adopt existing medicament forming technique to be processed into 986 capsules.
Embodiment 3.
Get Monas cuspurpureus Went 150g, Radix Salviae Miltiorrhizae 3300g, Ganoderma 5600g makes granule according to embodiment 1 described method, dry 506g, or make 1040 capsules.
Embodiment 4.
Get Monas cuspurpureus Went 220g, Radix Salviae Miltiorrhizae 2600g, Ganoderma 5500g makes granule according to embodiment 1 described method, dry 540g, or make 1308 capsules.
Embodiment 5.
Get Monas cuspurpureus Went 220g, Radix Salviae Miltiorrhizae 3200g, Ganoderma 4800g makes granule according to embodiment 1 described method, dry 521g, or make 1216 capsules.
Claims (5)
1. blood fat reducing Chinese medicine is characterized in that: by the weight of thousand amounts, get Monas cuspurpureus Went 150～220g, and Radix Salviae Miltiorrhizae 2500～3300g, Ganoderma 4800～5600g, and undertaken by following step successively,
A. Radix Salviae Miltiorrhizae alcohol heating reflux lixiviate twice, each 1.5 hours, the extracting solution merging was concentrated into rare paste;
B. Ganoderma powder is broken into coarse powder, decocts with water 2 times, each 3 hours, decocting liquid merged filtration;
C. with above-mentioned (a) and (b) the medicinal residues merging in step, add suitable quantity of water and decocted 2 hours, decocting liquid filters, and filtering decocting liquid and above-mentioned (b) step filtrate merge, and concentrated this filtrate is to rare paste;
D. with above-mentioned (a) and (c) rare paste merging in step, add Monas cuspurpureus Went fine powder and appropriate amount of auxiliary materials and make granule, drying.
2. according to the described blood fat reducing Chinese medicine of claim 1, it is characterized in that: to be respectively be 90% and 50% to twice used concentration of ethanol in described (a) step.
3. according to the described blood fat reducing Chinese medicine of claim 1, it is characterized in that: twice amount of water is respectively 10 times of amounts and 8 times of amounts of Ganoderma in described (b) step.
4. according to the described blood fat reducing Chinese medicine of claim 1, it is characterized in that: the amount of water in described (c) step is for merging 5 times of amounts of medicinal residues.
5. according to the described blood fat reducing Chinese medicine of claim 1, it is characterized in that: the dosage form of patent medicine is capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102186235A CN102038745B (en) | 2009-10-18 | 2009-10-18 | Hypolipidemic traditional Chinese medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102186235A CN102038745B (en) | 2009-10-18 | 2009-10-18 | Hypolipidemic traditional Chinese medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102038745A true CN102038745A (en) | 2011-05-04 |
| CN102038745B CN102038745B (en) | 2011-12-28 |
Family
ID=43905506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102186235A Expired - Fee Related CN102038745B (en) | 2009-10-18 | 2009-10-18 | Hypolipidemic traditional Chinese medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102038745B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103202471A (en) * | 2013-04-25 | 2013-07-17 | 福建永生活力生物工程有限公司 | Health food for reducing blood fat in auxiliary manner and preparation method of health food |
| CN103505507A (en) * | 2012-06-28 | 2014-01-15 | 天津天狮生物发展有限公司 | Traditional Chinese medicine composition containing glossy ganoderma and preparation method of composition |
| CN106075189A (en) * | 2016-07-22 | 2016-11-09 | 钦州市中医医院 | A kind of traditional Chinese medicine for lowering blood fat |
| CN106266736A (en) * | 2016-11-02 | 2017-01-04 | 天津中新药业集团股份有限公司达仁堂制药厂 | A kind of Chinese medicine composition assisting blood fat reducing and preparation method thereof |
| CN106491709A (en) * | 2016-12-30 | 2017-03-15 | 向关义 | A kind of Chinese medicine composition and preparation method thereof and the application in the medicine for preparing blood fat reducing |
| CN106581503A (en) * | 2017-02-24 | 2017-04-26 | 河北奥芬医药科技有限公司 | Blood fat reducing composition |
| CN111281971A (en) * | 2020-03-13 | 2020-06-16 | 张明洞 | Pharmaceutical composition capable of reducing blood viscosity |
| CN113521151A (en) * | 2021-08-23 | 2021-10-22 | 通化鑫业生物科技研发有限公司 | Compound active extract, preparation method thereof and anti-atherosclerosis drug |
-
2009
- 2009-10-18 CN CN2009102186235A patent/CN102038745B/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505507A (en) * | 2012-06-28 | 2014-01-15 | 天津天狮生物发展有限公司 | Traditional Chinese medicine composition containing glossy ganoderma and preparation method of composition |
| CN103202471A (en) * | 2013-04-25 | 2013-07-17 | 福建永生活力生物工程有限公司 | Health food for reducing blood fat in auxiliary manner and preparation method of health food |
| CN106075189A (en) * | 2016-07-22 | 2016-11-09 | 钦州市中医医院 | A kind of traditional Chinese medicine for lowering blood fat |
| CN106266736A (en) * | 2016-11-02 | 2017-01-04 | 天津中新药业集团股份有限公司达仁堂制药厂 | A kind of Chinese medicine composition assisting blood fat reducing and preparation method thereof |
| CN106491709A (en) * | 2016-12-30 | 2017-03-15 | 向关义 | A kind of Chinese medicine composition and preparation method thereof and the application in the medicine for preparing blood fat reducing |
| CN106581503A (en) * | 2017-02-24 | 2017-04-26 | 河北奥芬医药科技有限公司 | Blood fat reducing composition |
| CN111281971A (en) * | 2020-03-13 | 2020-06-16 | 张明洞 | Pharmaceutical composition capable of reducing blood viscosity |
| CN113521151A (en) * | 2021-08-23 | 2021-10-22 | 通化鑫业生物科技研发有限公司 | Compound active extract, preparation method thereof and anti-atherosclerosis drug |
| CN115463180A (en) * | 2021-08-23 | 2022-12-13 | 通化鑫业生物科技研发有限公司 | Compound active extract, preparation method thereof and anti-atherosclerosis drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102038745B (en) | 2011-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038745B (en) | Hypolipidemic traditional Chinese medicine | |
| CN1259935C (en) | Medicine for treating hyperlipemia | |
| CN102284022A (en) | Cough medicament and preparation method thereof | |
| CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN102579836B (en) | Traditional Chinese medical dendrobium huoshanense composition and preparation method thereof | |
| CN103479691A (en) | Lipid-decreasing liver protection traditional Chinese medicine composition | |
| CN1970021A (en) | Chinese medicine for treating gout and preparation method thereof | |
| CN1660287A (en) | Capsule for descend of blood fat and preparing method | |
| CN102309705A (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN1850160A (en) | Qidantongmai Tablet, and its preparing process | |
| CN101293081B (en) | Medicament for treating hyperlipemia and preparation method thereof | |
| CN102631425B (en) | Mongolian medicine for treating dyslipidemia | |
| CN103040983B (en) | Traditional Chinese medicine for preventing and/or treating premonitory apoplexy and preparation method thereof | |
| CN101279034A (en) | Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof | |
| CN102631498B (en) | Chinese medicine composition | |
| CN100363046C (en) | Prepn for treating fatty liver and alcoholic liver and its prepn process | |
| CN100488546C (en) | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method | |
| CN102614271A (en) | Chinese medicine for treating diabetic dyslipidemia | |
| CN104256618A (en) | Food, health care product or medicine composition with blood sugar reduction function | |
| CN1088450A (en) | The excellent blood fat reducing of preparation of treatment hyperlipidemia | |
| CN1762440A (en) | Medicine for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN1634541A (en) | Medicine for treating fatigue syndrome and preventing presenility, and preparation method thereof | |
| CN1626195A (en) | Preparation of Chinese traditional medicine for treating coronary heart disease and angina as well as preparation method | |
| CN1099290C (en) | Chinese medicine and its prescription for promoting blood circulation and reducing blood fat | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110504 Assignee: Shaanxi Shenlong Pharmaceutical Co.,Ltd. Assignor: Liao Dehong Contract record no.: 2012610000133 Denomination of invention: Traditional Chinese medicine composition for lowering blood fat, and prepn. method therefor Granted publication date: 20111228 License type: Exclusive License Record date: 20120807 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111228 Termination date: 20121018 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110504 Assignee: Shaanxi Shenlong Pharmaceutical Co.,Ltd. Assignor: Liao Dehong Contract record no.: 2012610000133 Denomination of invention: Traditional Chinese medicine composition for lowering blood fat, and prepn. method therefor Granted publication date: 20111228 License type: Exclusive License Record date: 20120807 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model |